Eastwood Bio-Medical Canada Inc. markets, develops research, and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia. The company distributes Eleotin, which provides natural remedies for metabolic disorders, such as blood glucose disorders, hypertension, and obesity. It also offers Eleotin A 700 for the treatment for spleen deficiency, lack of appetite, and fatigue; Eleotin AL88 for laxative; Eleotin Cal20 for bone and teeth maintenance; Eleotin V3D for bones, teeth, and health; Eleotin G2000 for cardiovascular health; Eleotin H55 for sedative and tension relief; and Eleotin Zn330 for tissue formation and metabolism. In addition, the company provides Eleotin Bentley to promote healthy glucose levels; and Eleotin LBM for hypertension relief. It has a joint research agreement with BioNexus Inc. to build a platform that applies artificial intelligence to herbal ingredient prescription data in order to identify natural drug and functional food product candidates. The company was incorporated in 2010 and is based in Richmond, Canada. Eastwood Bio-Medical Canada Inc. operates as a subsidiary of Eastwood Bio-Medical Research Inc.
Research context
Eastwood Bio-Medical Canada Inc appears in PyInvesting’s TSX Venture Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Eastwood Bio-Medical Canada Inc is currently in a long term downtrend where the price is trading 10.6% below its 200 day moving average.
From a valuation standpoint, the stock is 82.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 182.2.
Eastwood Bio-Medical Canada Inc's total revenue rose by 48.4% to $203K since the same quarter in the previous year.
Its net income has dropped by 13.2% to $-276K since the same quarter in the previous year.
Finally, its free cash flow grew by 81.4% to $-29K since the same quarter in the previous year.
Based on the above factors, Eastwood Bio-Medical Canada Inc gets an overall score of 3/5.